4.25
0.13 (3.03%)
| Penutupan Terdahulu | 4.12 |
| Buka | 4.10 |
| Jumlah Dagangan | 33,596 |
| Purata Dagangan (3B) | 332,119 |
| Modal Pasaran | 254,193,632 |
| Harga / Jualan (P/S) | 6.55 |
| Harga / Buku (P/B) | 5.79 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2026 |
| Margin Operasi (TTM) | -2,179.84% |
| EPS Cair (TTM) | -1.77 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 40.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 97.55% |
| Nisbah Semasa (MRQ) | 3.35 |
| Aliran Tunai Operasi (OCF TTM) | -54.06 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -28.16 M |
| Pulangan Atas Aset (ROA TTM) | -60.70% |
| Pulangan Atas Ekuiti (ROE TTM) | -179.12% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Orchestra BioMed Holdings, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.33 |
|
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 21.81% |
| % Dimiliki oleh Institusi | 49.62% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |